** Specialty pharma firm 60 Degrees Pharmaceuticals' SXTP.O shares rise 5.6% to 63 cents in afternoon trade
** Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.
** Arakoda is an antimalarial drug for the prophylaxis of malaria in patients aged 18 years and older in the U.S.
** The drug is sold under the brand name Kodatef in Australia
** The drug is not approved for use in the U.S.
** SXTP plans to import a five-month supply of Kodatef while increasing manufacturing of Arakoda over long term
** Co says the two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features
** In the last 12 months, stock has fallen 80.2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.